Omega-3 polyunsaturated fatty acids and cancer: lessons learned from clinical trials

Cancer and Metastasis Reviews

Volumn 34, Issue 3, 2015, Pages 359-380

  Nabavi, Seyed Fazel ^a   Bilotto, Stefania ^b   Russo, Gian Luigi ^b   Orhan, Ilkay Erdogan ^c   Habtemariam, Solomon ^d   Daglia, Maria ^e   Devi, Kasi Pandima ^f   Loizzo, Monica Rosa ^g   Tundis, Rosa ^g   Nabavi, Seyed Mohammad ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b CNR   (Italy)

^c GAZI UNIVERSITY   (Turkey)

^d UNIVERSITY OF GREENWICH   (United Kingdom)

^e UNIVERSITY OF PAVIA   (Italy)

^f ALAGAPPA UNIVERSITY   (India)

^g UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Cancer; Clinical trials; Nuclear factor B; Omega 3 FA

Indexed keywords

CD59 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OMEGA 3 FATTY ACID; PROSTAGLANDIN SYNTHASE; ANTINEOPLASTIC AGENT;

ARTICLE; BIOAVAILABILITY; BREAST CANCER; CACHEXIA; CANCER THERAPY; COLORECTAL CANCER; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG EFFICACY; DRUG TOLERABILITY; EGG YOLK; ENZYME ACTIVITY; ESOPHAGUS CANCER; FRESHWATER FISH; FRUIT; HEAD AND NECK CANCER; HUMAN; LEUKEMIA; LIPID RAFT; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PHYTOPLANKTON; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RED MEAT; STOMACH CANCER; THERAPY EFFECT; UPREGULATION; VEGETABLE; WHITE MEAT; NEOPLASMS;

ANTINEOPLASTIC AGENTS; FATTY ACIDS, OMEGA-3; HUMANS; NEOPLASMS;

EID: 84942197192     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-015-9572-2     Document Type: Article

References (275)

1. Jones, P. A., & Baylin, S. B. (2007). The epigenomics of cancer. Cell, 128(4), 683–692.
2. Bleyer, W. A. (2002). Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival, and importance of clinical trials. Medical and Pediatric Oncology, 38(1), 1–10.
3. Berman, J. J. (2004). Tumor classification: molecular analysis meets Aristotle. BMC Cancer, 4(1), 10.
4. Grady, W. M., & Markowitz, S. D. (2002). Genetic and epigenetic alterations in colon cancer. Annual Review of Genomics and Human Genetics, 3(1), 101–128.
5. Ames, B. N., Gold, L. S., & Willett, W. C. (1995). The causes and prevention of cancer. Proceedings of the National Academy of Sciences, 92(12), 5258–5265.
6. Peto, J. (2001). Cancer epidemiology in the last century and the next decade. Nature, 411(6835), 390–395.
7. Boffetta, P., Boccia, S., & La Vecchia, C. (2014). Overview of the major causes of human cancer. In A quick guide to cancer epidemiology (pp. 77-88): Springer.
8. Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014). Cancer statistics, 2014. CA: A Cancer Journal for Clinicians, 64(1), 9–29.
9. Harnack, L., Block, G., Subar, A., Lane, S., & Brand, R. (1997). Association of cancer prevention-related nutrition knowledge, beliefs, and attitudes to cancer prevention dietary behavior. Journal of the American Dietetic Association, 97(9), 957–965.
10. Beaglehole, R., Bonita, R., & Magnusson, R. (2011). Global cancer prevention: an important pathway to global health and development. Public Health, 125(12), 821–831.
11. Manca, A., Asseburg, C., Bravo Vergel, Y., Seymour, M. T., Meade, A., Stephens, R., et al. (2012). The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS). Value in Health, 15(1), 22–31.
12. Sher, D. J., Wee, J. O., & Punglia, R. S. (2011). Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer. International Journal of Radiation Oncology Biology Physics, 81(5), e767–e774.
13. Monsuez, J.-J., Charniot, J.-C., Vignat, N., & Artigou, J.-Y. (2010). Cardiac side-effects of cancer chemotherapy. International Journal of Cardiology, 144(1), 3–15.
14. Monje, M., & Dietrich, J. (2012). Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis. Behavioural Brain Research, 227(2), 376–379.
15. Eschenhagen, T., Force, T., Ewer, M. S., Keulenaer, G. W., Suter, T. M., Anker, S. D., et al. (2011). Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 13(1), 1–10.
16. Ihbe-Heffinger, A., Paessens, B., Berger, K., Shlaen, M., Bernard, R., von Schilling, C., et al. (2013). The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care—an observational analysis on non-small-cell lung cancer patients. Supportive Care in Cancer, 21(6), 1665–1675.
17. Love, R. R., Leventhal, H., Easterling, D. V., & Nerenz, D. R. (1989). Side effects and emotional distress during cancer chemotherapy. Cancer, 63(3), 604–612.
18. Terry, P., Lichtenstein, P., Feychting, M., Ahlbom, A., & Wolk, A. (2001). Fatty fish consumption and risk of prostate cancer. The Lancet, 357(9270), 1764–1766.
19. Szymanski, K. M., Wheeler, D. C., & Mucci, L. A. (2010). Fish consumption and prostate cancer risk: a review and meta-analysis. The American journal of clinical nutrition, 92(5), 1223–1233.
20. Turunen, A. W., Suominen, A. L., Kiviranta, H., Verkasalo, P. K., & Pukkala, E. (2014). Cancer incidence in a cohort with high fish consumption. Cancer Causes & Control, 25(12), 1595–1602.
21. Rohrmann, S., Linseisen, J., Nöthlings, U., Overvad, K., Egeberg, R., Tjønneland, A., et al. (2013). Meat and fish consumption and risk of pancreatic cancer: results from the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 132(3), 617–624.
22. Wu, S., Feng, B., Li, K., Zhu, X., Liang, S., Liu, X., et al. (2012). Fish consumption and colorectal cancer risk in humans: a systematic review and meta-analysis. The American Journal of Medicine, 125(6), 551–559.
23. MacLean, C. H., Newberry, S. J., Mojica, W. A., Khanna, P., Issa, A. M., Suttorp, M. J., et al. (2006). Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA, 295(4), 403–415.
24. Hooper, L., Thompson, R. L., Harrison, R. A., Summerbell, C. D., Ness, A. R., Moore, H. J., et al. (2006). Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ, 332(7544), 752–760.
25. Rose, D. P., & Connolly, J. M. (1999). Omega-3 fatty acids as cancer chemopreventive agents. Pharmacology & Therapeutics, 83(3), 217–244.
26. Larsson, S. C., Kumlin, M., Ingelman-Sundberg, M., & Wolk, A. (2004). Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. The American Journal of Clinical Nutrition, 79(6), 935–945.
27. Kapoor, R., & Patil, U. (2011). Importance and production of omega-3 fatty acids from natural sources. International Food Research Journal, 18, 493–499.
28. Pawlosky, R. J., Hibbeln, J. R., Novotny, J. A., & Salem, N. (2001). Physiological compartmental analysis of α-linolenic acid metabolism in adult humans. Journal of Lipid Research, 42(8), 1257–1265.
29. Booyens, J., Engelbrecht, P., Le Roux, S., Louwrens, C., Van der Merwe, C., & Katzeff, I. (1984). Some effects of the essential fatty acids linoleic acid and alpha-linolenic acid and of their metabolites gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, and of prostaglandins A1 and E1 on the proliferation of human osteogenic sarcoma cells in culture. Prostaglandins, Leukotrienes, and Medicine, 15(1), 15–33.
30. Das, U. N. (2006). Essential fatty acids: biochemistry, physiology and pathology. Biotechnology Journal, 1(4), 420–439.
31. Das, U. N. (2006). Essential fatty acids—a review. Current Pharmaceutical Biotechnology, 7(6), 467–482.
32. Brenna, J. T., Salem, N., Jr., Sinclair, A. J., & Cunnane, S. C. (2009). α-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins, Leukotrienes and Essential Fatty Acids, 80(2), 85–91.
33. Lopez-Garcia, E., Schulze, M. B., Manson, J. E., Meigs, J. B., Albert, C. M., Rifai, N., et al. (2004). Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. The Journal of Nutrition, 134(7), 1806–1811.
34. Kidd, P. M. (2007). Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. Alternative Medicine Review, 12(3), 207.
35. Simopoulos, A. P. (1991). Omega-3 fatty acids in health and disease and in growth and development. The American Journal of Clinical Nutrition, 54(3), 438–463.
36. Meyer, B. J., Mann, N. J., Lewis, J. L., Milligan, G. C., Sinclair, A. J., & Howe, P. R. (2003). Dietary intakes and food sources of omega-6 and omega-3 polyunsaturated fatty acids. Lipids, 38(4), 391–398.
37. Simopoulos, A. P. (2004). Omega-3 fatty acids and antioxidants in edible wild plants. Biological Research, 37(2), 263–277.
38. Ratnayake, W. N., & Galli, C. (2009). Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: a background review paper. Annals of Nutrition and Metabolism, 55(1-3), 8–43.
39. Brash, A. R. (2001). Arachidonic acid as a bioactive molecule. The Journal of Clinical Investigation, 107(11), 1339–1345.
40. Piomelli, D. (1993). Arachidonic acid in cell signaling. Current Opinion in Cell Biology, 5(2), 274–280.
41. Zahringer, U., Domergue, F., Abbadi, A., Moreau, H. x. e., & Heinz, E. (2005). In vivo characterization of the first acyl-CoA Delta6-desaturase from a member of the plant kingdom, the microalga Ostreococcus tauri. Biochemical Journal, 389, 483–490.
42. Ryckebosch, E., Bruneel, C., Muylaert, K., & Foubert, I. (2012). Microalgae as an alternative source of omega‐3 long chain polyunsaturated fatty acids. Lipid Technology, 24(6), 128–130.
43. Chen, Y., Meesapyodsuk, D., & Qiu, X. (2014). Transgenic production of omega-3 very long chain polyunsaturated fatty acids in plants: accomplishment and challenge. Biocatalysis and Agricultural Biotechnology, 3(1), 38–43.
44. Simopoulos, A. (2000). Human requirement for N-3 polyunsaturated fatty acids. Poultry Science, 79(7), 961–970.
45. Belury, M. A. (1995). Conjugated dienoic linoleate: a polyunsaturated fatty acid with unique chemoprotective properties. Nutrition Reviews, 53(4), 83–89.
46. Tapiero, H., Nguyen Ba, G., Couvreur, P., & Tew, K. (2002). Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomedicine & Pharmacotherapy, 56(5), 215–222.
47. Kurlak, L., & Stephenson, T. (1999). Plausible explanations for effects of long chain polyunsaturated fatty acids (LCPUFA) on neonates. Archives of Disease in Childhood-Fetal and Neonatal Edition, 80(2), F148–F154.
48. Jump, D. B. (2002). The biochemistry of n-3 polyunsaturated fatty acids. Journal of Biological Chemistry, 277(11), 8755–8758.
49. Astorg, P., Arnault, N., Czernichow, S., Noisette, N., Galan, P., & Hercberg, S. (2004). Dietary intakes and food sources of n-6 and n-3 PUFA in French adult men and women. Lipids, 39(6), 527–535.
50. Williams, C. M., & Burdge, G. (2006). Long-chain n-3 PUFA: plant v. marine sources. Proceedings of the Nutrition Society, 65(01), 42–50.
51. Kolanowski, W. (1999). Possibilities of fish oil application for food products enrichment with omega-3 PUFA. International Journal of Food Sciences and Nutrition, 50(1), 39–49.
52. Kris-Etherton, P., Taylor, D. S., Yu-Poth, S., Huth, P., Moriarty, K., Fishell, V., et al. (2000). Polyunsaturated fatty acids in the food chain in the United States. The American Journal of Clinical Nutrition, 71(1), 179S–188S.
53. Racine, R. A., & Deckelbaum, R. J. (2007). Sources of the very-long-chain unsaturated omega-3 fatty acids: eicosapentaenoic acid and docosahexaenoic acid. Current Opinion in Clinical Nutrition and Metabolic Care, 10(2), 123–128.
54. Pacetti, D., Mozzon, M., Lucci, P., & Frega, N. G. (2013). Bioactive fish fatty acids: health effects and their use as functional food ingredients. Current Nutrition and Food Science, 9(4), 283–297.
55. Martins, D. A., Custódio, L., Barreira, L., Pereira, H., Ben-Hamadou, R., Varela, J., et al. (2013). Alternative sources of n-3 long-chain polyunsaturated fatty acids in marine microalgae. Marine Drugs, 11(7), 2259–2281.
56. Collins, M., Lynch, B., Barfield, W., Bull, A., Ryan, A., & Astwood, J. (2014). Genetic and acute toxicological evaluation of an algal oil containing eicosapentaenoic acid (EPA) and palmitoleic acid. Food and Chemical Toxicology, 72, 162–168.
57. Whelan, J., & Rust, C. (2006). Innovative dietary sources of n-3 fatty acids. Annual Review of Nutrition, 26, 75–103.
58. Ahmad, S., Yousaf, M., Sabri, M. A., & Kamran, Z. (2012). Response of laying hens to omega-3 fatty acids for performance and egg quality. Avian Biology Research, 5(1), 1–10.
59. Simopoulos, A. P. (2002). Omega‐3 fatty acids in wild plants, nuts and seeds. Asia Pacific Journal of Clinical Nutrition, 11(s6), S163–S173.
60. Ribeiro, B., Guedes de Pinho, P., Andrade, P. B., Baptista, P., & Valentão, P. (2009). Fatty acid composition of wild edible mushrooms species: a comparative study. Microchemical Journal, 93(1), 29–35.
61. Meluzzi, A., Sirri, F., Manfreda, G., Tallarico, N., & Franchini, A. (2000). Effects of dietary vitamin E on the quality of table eggs enriched with n-3 long-chain fatty acids. Poultry Science, 79(4), 539–545.
62. Shapira, N., Weill, P., & Loewenbach, R. (2008). Egg fortification with n-3 polyunsaturated fatty acids (PUFA): nutritional benefits versus high n-6 PUFA western diets, and consumer acceptance. The Israel Medical Association Journal: IMAJ, 10(4), 262–265.
63. Farrell, D. J. (1998). Enrichment of hen eggs with n-3 long-chain fatty acids and evaluation of enriched eggs in humans. The American Journal of Clinical Nutrition, 68(3), 538–544.
64. Lopez-Bote, C., Sanz Arias, R., Rey, A., Castano, A., Isabel, B., & Thos, J. (1998). Effect of free-range feeding on n-3 fatty acid and α-tocopherol content and oxidative stability of eggs. Animal Feed Science and Technology, 72(1), 33–40.
65. Herber, S., & Van Elswyk, M. (1996). Dietary marine algae promotes efficient deposition of n-3 fatty acids for the production of enriched shell eggs. Poultry Science, 75(12), 1501–1507.
66. Van Elswyk, M. E. (1997). Comparison of n–3 fatty acid sources in laying hen rations for improvement of whole egg nutritional quality: a review. British Journal of Nutrition, 78(01), S61–S69.
67. Fredriksson, S., Elwinger, K., & Pickova, J. (2006). Fatty acid and carotenoid composition of egg yolk as an effect of microalgae addition to feed formula for laying hens. Food Chemistry, 99(3), 530–537.
68. Alfaia, C. P., Alves, S. P., Martins, S., IV, Costa, A. S., Fontes, C. M., Lemos, J. P., et al. (2009). Effect of the feeding system on intramuscular fatty acids and conjugated linoleic acid isomers of beef cattle, with emphasis on their nutritional value and discriminatory ability. Food Chemistry, 114(3), 939–946.
69. Leheska, J., Thompson, L., Howe, J., Hentges, E., Boyce, J., Brooks, J., et al. (2008). Effects of conventional and grass-feeding systems on the nutrient composition of beef. Journal of Animal Science, 86(12), 3575–3585.
70. Richardson, R. I., Ender, K., Nute, G., Scollan, N. D., Nuernberg, K., Voigt, J., et al. Effect of a grass-based and a concentrate feeding system on meat quality characteristics and fatty acid composition of longissimus muscle in different cattle breeds. different cattle breeds. Livestock Production Science.
71. Realini, C., Duckett, S., Brito, G., Dalla Rizza, M., & De Mattos, D. (2004). Effect of pasture vs. concentrate feeding with or without antioxidants on carcass characteristics, fatty acid composition, and quality of Uruguayan beef. Meat Science, 66(3), 567–577.
72. Warren, H., Enser, M., Richardson, I., Wood, J., & Scollan, N. Effect of breed and diet on total lipid and selected shelf-life parameters in beef muscle. In Proceedings of British Society of animal science, 2003 (Vol. 23)
73. Ponnampalam, E., Mann, N., & Sinclair, A. (2006). Effect of feeding systems on omega-3 fatty acids, conjugated linoleic acid and trans fatty acids in Australian beef cuts: potential impact on human health. Asia Pacific Journal of Clinical Nutrition, 15(1), 21–29.
74. Fisher, A., Enser, M., Richardson, R., Wood, J., Nute, G., Kurt, E., et al. (2000). Fatty acid composition and eating quality of lamb types derived from four diverse breed × production systems. Meat Science, 55(2), 141–147.
75. Sanudo, C., Enser, M., Campo, M., Nute, G., Marıa, G., Sierra, I., et al. (2000). Fatty acid composition and sensory characteristics of lamb carcasses from Britain and Spain. Meat Science, 54(4), 339–346.
76. Ayerza, R., Coates, W., & Lauria, M. (2002). Chia seed (Salvia hispanica L.) as an omega-3 fatty acid source for broilers: influence on fatty acid composition, cholesterol and fat content of white and dark meats, growth performance, and sensory characteristics. Poultry Science, 81(6), 826–837.
77. Simopoulos, A. P. (2001). n-3 Fatty acids and human health: defining strategies for public policy. Lipids, 36(1), S83–S89.
78. Lopez-Ferrer, S., Baucells, M., Barroeta, A., & Grashorn, M. (1999). N-3 enrichment of chicken meat using fish oil: alternative substitution with rapeseed and linseed oils. Poultry Science, 78(3), 356–365.
79. Azcona, J. O., Schang, M. J., Garcia, P. T., Gallinger, C., Ayerza, R., Jr., & Coates, W. (2008). Omega-3 enriched broiler meat: the influence of dietary α-linolenic-ω-3 fatty acid sources on growth, performance and meat fatty acid composition. Canadian Journal of Animal Science, 88(2), 257–269.
80. Kopecky, J., Rossmeisl, M., Flachs, P., Kuda, O., Brauner, P., Jilkova, Z., et al. (2009). n-3 PUFA: bioavailability and modulation of adipose tissue function. Proceedings of the Nutrition Society, 68(04), 361–369.
81. Dyerberg, J., Madsen, P., Møller, J. M., Aardestrup, I., & Schmidt, E. B. (2010). Bioavailability of marine n-3 fatty acid formulations. Prostaglandins, Leukotrienes and Essential Fatty Acids, 83(3), 137–141.
82. Wallace, J., McCabe, A., Robson, P., Keogh, M., Murray, C., Kelly, P., et al. (2000). Bioavailability of n-3 polyunsaturated fatty acids (PUFA) in foods enriched with microencapsulated fish oil. Annals of Nutrition and Metabolism, 44(4), 157–162.
83. Nagakura, T., Matsuda, S., Shichijyo, K., Sugimoto, H., & Hata, K. (2000). Dietary supplementation with fish oil rich in omega-3 polyunsaturated fatty acids in children with bronchial asthma. European Respiratory Journal, 16(5), 861–865.
84. Sargent, J., Bell, G., McEvoy, L., Tocher, D., & Estevez, A. (1999). Recent developments in the essential fatty acid nutrition of fish. Aquaculture, 177(1), 191–199.
85. Rogers, S., James, K. S., Butland, B. K., Etherington, M., O'Brien, J., & Jones, J. (1987). Effects of a fish oil supplement on serum lipids, blood pressure, bleeding time, haemostatic and rheological variables: a double blind randomised controlled trial in healthy volunteers. Atherosclerosis, 63(2), 137–143.
86. Schuchardt, J. P., Schneider, I., Meyer, H., Neubronner, J., von Schacky, C., & Hahn, A. (2011). Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations-a comparative bioavailability study of fish oil vs. krill oil. Lipids in Health and Disease, 10(1), 145.
87. Harris, W. S., Pottala, J. V., Sands, S. A., & Jones, P. G. (2007). Comparison of the effects of fish and fish-oil capsules on the n-3 fatty acid content of blood cells and plasma phospholipids. The American Journal of Clinical Nutrition, 86(6), 1621–1625.
88. Barrow, C. J., Nolan, C., & Holub, B. J. (2009). Bioequivalence of encapsulated and microencapsulated fish-oil supplementation. Journal of Functional Foods, 1(1), 38–43.
89. Bourre, J. (2004). Roles of unsaturated fatty acids (especially omega-3 fatty acids) in the brain at various ages and during ageing. J Nutr Health Aging, 8(3), 163–74.
90. Arterburn, L. M., Hall, E. B., & Oken, H. (2006). Distribution, interconversion, and dose response of n-3 fatty acids in humans. The American Journal of Clinical Nutrition, 83(6), S1467–1476S.
91. Flachs, P., Rossmeisl, M., Bryhn, M., & Kopecky, J. (2009). Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism. Clinical Science, 116, 1–16.
92. Ruzickova, J., Rossmeisl, M., Prazak, T., Flachs, P., Sponarova, J., Vecka, M., et al. (2004). Omega-3 PUFA of marine origin limit diet-induced obesity in mice by reducing cellularity of adipose tissue. Lipids, 39(12), 1177–1185.
93. Kuda, O., Jelenik, T., Jilkova, Z., Flachs, P., Rossmeisl, M., Hensler, M., et al. (2009). n-3 Fatty acids and rosiglitazone improve insulin sensitivity through additive stimulatory effects on muscle glycogen synthesis in mice fed a high-fat diet. Diabetologia, 52(5), 941–951.
94. Cansell, M., Nacka, F., & Combe, N. (2003). Marine lipid-based liposomes increase in vivo FA bioavailability. Lipids, 38(5), 551–559.
95. Vidgren, H. M., Ågren, J. J., Schwab, U., Rissanen, T., Hänninen, O., & Uusitupa, M. I. (1997). Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men. Lipids, 32(7), 697–705.
96. Saw, C. L., Yang, A. Y., Guo, Y., & Kong, A. N. (2013). Astaxanthin and omega-3 fatty acids individually and in combination protect against oxidative stress via the Nrf2-ARE pathway. Food and Chemical Toxicology: an International Journal Published for the British Industrial Biological Research Association, 62, 869–875.
97. Russo, G. L. (2009). Dietary n-6 and n-3 polyunsaturated fatty acids: From biochemistry to clinical implications in cardiovascular prevention. Biochemical Pharmacology, 77(6), 937–946.
98. Gerber, M. (2012). Omega-3 fatty acids and cancers: a systematic update review of epidemiological studies. The British Journal of Nutrition, 107(Suppl 2), S228–S239.
99. Berquin, I. M., Edwards, I. J., Kridel, S. J., & Chen, Y. Q. (2011). Polyunsaturated fatty acid metabolism in prostate cancer. Cancer Metastasis Reviews, 30(3-4), 295–309.
100. Larsson, S. C., Kumlin, M., Ingelman-Sundberg, M., & Wolk, A. (2004). Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. The American Journal of Clinical Nutrition, 79(6), 935–945.
101. Li, Q., Tan, L., Wang, C., Li, N., Li, Y., Xu, G., et al. (2006). Polyunsaturated eicosapentaenoic acid changes lipid composition in lipid rafts. European Journal of Nutrition, 45(3), 144–151.
102. Corsetto, P. A., Cremona, A., Montorfano, G., Jovenitti, I. E., Orsini, F., Arosio, P., et al. (2012). Chemical-physical changes in cell membrane microdomains of breast cancer cells after omega-3 PUFA incorporation. Cell Biochemistry and Biophysics, 64(1), 45–59.
103. Hardman, W. E. (2004). (n-3) fatty acids and cancer therapy. The Journal of Nutrition, 134(12 Suppl), 3427S–3430S.
104. Schley, P. D., Brindley, D. N., & Field, C. J. (2007). (n-3) PUFA alter raft lipid composition and decrease epidermal growth factor receptor levels in lipid rafts of human breast cancer cells. The Journal of Nutrition, 137(3), 548–553.
105. Rogers, K. R., Kikawa, K. D., Mouradian, M., Hernandez, K., McKinnon, K. M., Ahwah, S. M., et al. (2010). Docosahexaenoic acid alters epidermal growth factor receptor-related signaling by disrupting its lipid raft association. Carcinogenesis, 31(9), 1523–1530.
106. Kikawa, K. D., Herrick, J. S., Tateo, R. E., Mouradian, M., Tay, J. S., & Pardini, R. S. (2010). Induced oxidative stress and cell death in the A549 lung adenocarcinoma cell line by ionizing radiation is enhanced by supplementation with docosahexaenoic acid. Nutrition and Cancer, 62(8), 1017–1024.
107. Mouradian, M., Kikawa, K. D., Johnson, E. D., Beck, K. L., & Pardini, R. S. (2014). Key roles for GRB2-associated-binding protein 1, phosphatidylinositol-3-kinase, cyclooxygenase 2, prostaglandin E2 and transforming growth factor alpha in linoleic acid-induced upregulation of lung and breast cancer cell growth. Prostaglandins, Leukotrienes and Essential Fatty Acids, 90(4), 105–115.
108. Abulrob, A. N., Mason, M., Bryce, R., & Gumbleton, M. (2000). The effect of fatty acids and analogues upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance. Journal of Drug Targeting, 8(4), 247–256.
109. Abdia, J., Garssena, J., Faberb, J., & Redegeld, F. A. (2014). Omega-3 fatty acids, EPA and DHA induce apoptosis and enhance drug sensitivity in multiple myeloma cells but not in normal peripheral mononuclear cells. The Journal of Nutritional Biochemistry, 14, S0955–S2863.
110. Schley, P. D., Jijon, H. B., Robinson, L. E., & Field, C. J. (2005). Mechanisms of omega-3 fatty acid-induced growth inhibition in MDA-MB-231 human breast cancer cells. Breast Cancer Research and Treatment, 92(2), 187–195.
111. Jeong S, J. K., Kim N, Shin S, Kim S, Song KS, Heo JY, Park JH, Seo KS, Han J, Wu T, Kweon GR, Park SK, Park JI, Lim K (2014). Docosahexaenoic acid-induced apoptosis is mediated by activation of mitogen-activated protein kinases in human cancer cells. Jeong S, Jing K, Kim N, Shin S, Kim S, Song KS, Heo JY, Park JH, Seo KS, Han J, Wu T, Kweon GR, Park SK, Park JI, Lim K, 3(14), 481.
112. Kapoor, S. (2009). Immunomodulatory properties of omega-3 fatty acids: a possible explanation for their systemic, anti-carcinogenic effects. Journal of Leukocyte Biology, 85(1), 2–3.
113. Corsetto, P. A., Montorfano, G., Zava, S., Jovenitti, I. E., Cremona, A., Berra, B., et al. (2011). Effects of n-3 PUFAs on breast cancer cells through their incorporation in plasma membrane. Lipids in health and disease, 10, 73.
114. Xue, M., Wang, Q., Zhao, J., Dong, L., Ge, Y., Hou, L., et al. (2014). Docosahexaenoic acid inhibited the Wnt/beta-catenin pathway and suppressed breast cancer cells in vitro and in vivo. The Journal of Nutritional Biochemistry, 25(2), 104–110.
115. Dyari, H. R., Rawling, T., Bourget, K., & Murray, M. (2014). Synthetic omega-3 epoxyfatty acids as antiproliferative and Pro-apoptotic agents in human breast cancer cells. Journal of Medicinal Chemistry, 57(17), 7459–7464.
116. Mandal, C. C., Ghosh-Choudhury, T., Dey, N., Choudhury, G. G., & Ghosh-Choudhury, N. (2012). miR-21 is targeted by omega-3 polyunsaturated fatty acid to regulate breast tumor CSF-1 expression. Carcinogenesis, 33(10), 1897–1908.
117. Thiebaut, A. C., Chajes, V., Gerber, M., Boutron-Ruault, M. C., Joulin, V., Lenoir, G., et al. (2009). Dietary intakes of omega-6 and omega-3 polyunsaturated fatty acids and the risk of breast cancer. International Journal of Cancer Journal International Du Cancer, 124(4), 924–931.
118. Witt, P. M., Christensen, J. H., Schmidt, E. B., Dethlefsen, C., Tjonneland, A., Overvad, K., et al. (2009). Marine n-3 polyunsaturated fatty acids in adipose tissue and breast cancer risk: a case-cohort study from Denmark. Cancer Causes and Control: CCC, 20(9), 1715–1721.
119. Brasky, T. M., Lampe, J. W., Potter, J. D., Patterson, R. E., & White, E. (2010). Specialty supplements and breast cancer risk in the VITamins And Lifestyle (VITAL) Cohort. Cancer Epidemiology, Biomarkers and Prevention: a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 19(7), 1696–1708.
120. Bougnoux, P., Hajjaji, N., Ferrasson, M. N., Giraudeau, B., Couet, C., & Le Floch, O. (2009). Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. British Journal of Cancer, 101(12), 1978–1985.
121. Siegel, R., Desantis, C., & Jemal, A. (2014). Colorectal cancer statistics, 2014. CA: a Cancer Journal for Clinicians, 64(2), 104–117.
122. Yang, K., Yang, W., Mariadason, J., Velcich, A., Lipkin, M., & Augenlicht, L. (2005). Dietary components modify gene expression: implications for carcinogenesis. The Journal of Nutrition, 135(11), 2710–2714.
123. Fini, L., Piazzi, G., Ceccarelli, C., Daoud, Y., Belluzzi, A., Munarini, A., et al. (2010). Highly purified eicosapentaenoic acid as free fatty acids strongly suppresses polyps in Apc(Min/+) mice. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 16(23), 5703–5711.
124. Skendera, B., Hofmanováa, J., Slavíkc, J., Jelínkováa, I., Machalac, M., Pat Moyerd, M., et al. (2014). Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1841(9), 1308–1317.
125. Cai, F., Sorg, O., Granci, V., Lecumberri, E., Miralbell, R., Dupertuis, Y. M., et al. (2014). Interaction of omega-3 polyunsaturated fatty acids with radiation therapy in two different colorectal cancer cell lines. Clinical Nutrition, 33(1), 164–170.
126. Vasudevan, A., Yu, Y., Banerjee, S., Woods, J., Farhana, L., Rajendra, S. G., et al. (2014). Omega-3 fatty acid is a potential preventive agent for recurrent colon cancer. Cancer Prevention Research, 7(11), 1138–1148.
127. De Carlo, F., Witte, T. R., Hardman, W. E., & Claudio, P. P. (2013). Omega-3 eicosapentaenoic acid decreases CD133 colon cancer stem-like cell marker expression while increasing sensitivity to chemotherapy. PloS One, 8(7), e69760.
128. Makar, K. W., Poole, E. M., Resler, A. J., Seufert, B., Curtin, K., Kleinstein, S. E., et al. (2013). COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations. Cancer Causes and Control: CCC, 24(12), 2059–2075.
129. Habermann, N., Ulrich, C. M., Lundgreen, A., Makar, K. W., Poole, E. M., Caan, B., et al. (2013). PTGS1, PTGS2, ALOX5, ALOX12, ALOX15, and FLAP SNPs: interaction with fatty acids in colon cancer and rectal cancer. Genes and nutrition, 8(1), 115–126.
130. Higurashi, T., Hosono, K., Endo, H., Takahashi, H., Iida, H., Uchiyama, T., et al. (2012). Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial. [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]. BMC cancer, 12, 413.
131. Ceccarelli, V., Racanicchi, S., Martelli, M. P., Nocentini, G., Fettucciari, K., Riccardi, C., et al. (2011). Eicosapentaenoic acid demethylates a single CpG that mediates expression of tumor suppressor CCAAT/enhancer-binding protein delta in U937 leukemia cells. The Journal of Biological Chemistry, 286(31), 27092–27102
132. Ceccarelli, V., Nocentini, G., Billi, M., Racanicchi, S., Riccardi, C., Roberti, R., et al. (2014). Eicosapentaenoic acid activates RAS/ERK/C/EBPbeta pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. PloS One, 9(1), e85025.
133. Chiu, L. C., Ooi, V. E., & Wan, J. M. (2001). Eicosapentaenoic acid modulates cyclin expression and arrests cell cycle progression in human leukemic K-562 cells. International Journal of Oncology, 19(4), 845–849.
134. Gillis, R. C., Daley, B. J., Enderson, B. L., Kestler, D. P., & Karlstad, M. D. (2007). Regulation of apoptosis in eicosapentaenoic acid-treated HL-60 cells. The Journal of Surgical Research, 137(1), 141–150.
135. Hegde, S., Kaushal, N., Ravindra, K. C., Chiaro, C., Hafer, K. T., Gandhi, U. H., et al. (2011). Delta12-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells in mice. Blood, 118(26), 6909–6919.
136. Altenburg, J. D., Harvey, K. A., McCray, S., Xu, Z., & Siddiqui, R. A. (2011). A novel 2,6-diisopropylphenyl-docosahexaenoamide conjugate induces apoptosis in T cell acute lymphoblastic leukemia cell lines. Biochemical and Biophysical Research Communications, 411(2), 427–432.
137. Zhou, J., & Chng, W. J. (2014). Identification and targeting leukemia stem cells: the path to the cure for acute myeloid leukemia. World Journal of Stem Cells, 6(4), 473–484.
138. Yamagami, T., Porada, C. D., Pardini, R. S., Zanjani, E. D., & Almeida-Porada, G. (2009). Docosahexaenoic acid induces dose dependent cell death in an early undifferentiated subtype of acute myeloid leukemia cell line. Cancer Biology & Therapy, 8(4), 331–337.
139. Zhuo, Z., Zhang, L., Mu, Q., Lou, Y., Gong, Z., Shi, Y., et al. (2009). The effect of combination treatment with docosahexaenoic acid and 5-fluorouracil on the mRNA expression of apoptosis-related genes, including the novel gene BCL2L12, in gastric cancer cells. In Vitro Cellular & Developmental Biology. Animal, 45(1-2), 69–74.
140. Otto, C., Kaemmerer, U., Illert, B., Muehling, B., Pfetzer, N., Wittig, R., et al. (2008). Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. [Comparative Study Research Support, Non-U.S. Gov't]. BMC cancer, 8, 122.
141. Farreras, N., Artigas, V., Cardona, D., Rius, X., Trias, M., & Gonzalez, J. A. (2005). Effect of early postoperative enteral immunonutrition on wound healing in patients undergoing surgery for gastric cancer. Clinical Nutrition, 24(1), 55–65.
142. Daly, J. M., Weintraub, F. N., Shou, J., Rosato, E. F., & Lucia, M. (1995). Enteral nutrition during multimodality therapy in upper gastrointestinal cancer patients. Annals of Surgery, 221(4), 327–338.
143. Braga, M., Vignali, A., Gianotti, L., Cestari, A., Profili, M., & Di Carlo, V. (1995). Benefits of early postoperative enteral feeding in cancer patients. Infusionstherapie und Transfusionsmedizin, 22(5), 280–284.
144. Arshad, A., Chung, W. Y., Isherwood, J., Mann, C. D., Al-Leswas, D., Steward, W. P., et al. (2014). Cellular and plasma uptake of parenteral omega-3 rich lipid emulsion fatty acids in patients with advanced pancreatic cancer. Clinical Nutrition, 33(5), 895–899.
145. Arshad, A., Chung, W. Y., Steward, W., Metcalfe, M. S., & Dennison, A. R. (2013). Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil. HPB (Oxford), 15(6), 428–432.
146. Gong, Z., Holly, E. A., Wang, F., Chan, J. M., & Bracci, P. M. (2010). Intake of fatty acids and antioxidants and pancreatic cancer in a large population-based case-control study in the San Francisco Bay Area. International Journal of Cancer, 127(8), 1893–1904.
147. Strouch, M. J., Ding, Y., Salabat, M. R., Melstrom, L. G., Adrian, K., Quinn, C., et al. (2011). A high omega-3 fatty acid diet mitigates murine pancreatic precancer development. Journal of Surgical Research, 165(1), 75–81.
148. MacLean, C. H., Newberry, S. J., Mojica, W. A., Khanna, P., Issa, A. M., Suttorp, M. J., et al. (2006). Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA, 295(4), 403–415.
149. Hering, J., Garrean, S., Dekoj, T. R., Razzak, A., Saied, A., Trevino, J., et al. (2007). Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells. Annals of Surgical Oncology, 14(12), 3620–3628.
150. Song, K. S., Jing, K., Kim, J. S., Yun, E. J., Shin, S., Seo, K. S., et al. (2011). Omega-3-polyunsaturated fatty acids suppress pancreatic cancer cell growth in vitro and in vivo via downregulation of Wnt/Beta-catenin signaling. Pancreatology, 11(6), 574–584.
151. Fukui, M., Kang, K. S., Okada, K., & Zhu, B. T. (2013). EPA, an omega-3 fatty acid, induces apoptosis in human pancreatic cancer cells: role of ROS accumulation, caspase-8 activation, and autophagy induction. Journal of Cellular Biochemistry, 114(1), 192–203.
152. Godley, P. A., Campbell, M. K., Gallagher, P., Martinson, F. E., Mohler, J. L., & Sandler, R. S. (1996). Biomarkers of essential fatty acid consumption and risk of prostatic carcinoma. Cancer Epidemiology, Biomarkers and Prevention, 5(11), 889–895.
153. Norrish, A. E., Skeaff, C. M., Arribas, G. L., Sharpe, S. J., & Jackson, R. T. (1999). Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. British Journal of Cancer, 81(7), 1238–1242.
154. Kobayashi, M., Sasaki, S., Hamada, G. S., & Tsugane, S. (1999). Serum n-3 fatty acids, fish consumption and cancer mortality in six Japanese populations in Japan and Brazil. Japanese Journal of Cancer Research, 90(9), 914–921.
155. Aronson, W. J., Barnard, R. J., Freedland, S. J., Henning, S., Elashoff, D., Jardack, P. M., et al. (2010). Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer. Journal of Urology, 183(1), 345–350.
156. Brasky, T. M., Till, C., White, E., Neuhouser, M. L., Song, X., Goodman, P., et al. (2011). Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. American Journal of Epidemiology, 173(12), 1429–1439.
157. Brasky, T. M., Darke, A. K., Song, X., Tangen, C. M., Goodman, P. J., Thompson, I. M., et al. (2013). Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. Journal of the National Cancer Institute, 105(15), 1132–1141.
158. Brouwer, I. A., Geleijnse, J. M., Klaasen, V. M., Smit, L. A., Giltay, E. J., de Goede, J., et al. (2013). Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the alpha omega trial. PloS One, 8(12), e81519.
159. Alexander, W. (2013). Prostate cancer risk and omega-3 fatty acid intake from fish oil: a closer look at media messages versus research findings. Pharmacy and Therapeutics, 38(9), 561–564.
160. Koralek, D. O., Peters, U., Andriole, G., Reding, D., Kirsh, V., Subar, A., et al. (2006). A prospective study of dietary alpha-linolenic acid and the risk of prostate cancer (United States). Cancer Causes and Control, 17(6), 783–791.
161. Berquin, I. M., Min, Y., Wu, R., Wu, J., Perry, D., Cline, J. M., et al. (2007). Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. Journal of Clinical Investigation, 117(7), 1866–1875.
162. Akinsete, J. A., Ion, G., Witte, T. R., & Hardman, W. E. (2012). Consumption of high omega-3 fatty acid diet suppressed prostate tumorigenesis in C3(1) Tag mice. Carcinogenesis, 33(1), 140–148.
163. Cavazos, D. A., Price, R. S., Apte, S. S., & deGraffenried, L. A. (2011). Docosahexaenoic acid selectively induces human prostate cancer cell sensitivity to oxidative stress through modulation of NF-kappaB. Prostate, 71(13), 1420–1428.
164. Shin, S., Jing, K., Jeong, S., Kim, N., Song, K. S., Heo, J. Y., et al. (2013). The omega-3 polyunsaturated fatty acid DHA induces simultaneous apoptosis and autophagy via mitochondrial ROS-mediated Akt-mTOR signaling in prostate cancer cells expressing mutant p53. Biomed Research International, 2013, 568671.
165. Gu, Z., Suburu, J., Chen, H., & Chen, Y. Q. (2013). Mechanisms of omega-3 polyunsaturated fatty acids in prostate cancer prevention. Biomed Research International, 2013, 824563.
166. Veierod, M. B., Laake, P., & Thelle, D. S. (1997). Dietary fat intake and risk of lung cancer: a prospective study of 51,452 Norwegian men and women. European Journal of Cancer Prevention, 6(6), 540–549.
167. Suzuki, S., Akechi, T., Kobayashi, M., Taniguchi, K., Goto, K., Sasaki, S., et al. (2004). Daily omega-3 fatty acid intake and depression in Japanese patients with newly diagnosed lung cancer. British Journal of Cancer, 90(4), 787–793.
168. Kobayakawa, M., Yamawaki, S., Hamazaki, K., Akechi, T., Inagaki, M., & Uchitomi, Y. (2005). Levels of omega-3 fatty acid in serum phospholipids and depression in patients with lung cancer. British Journal of Cancer, 93(12), 1329–1333.
169. Yao, Q. H., Zhang, X. C., Fu, T., Gu, J. Z., Wang, L., Wang, Y., et al. (2014). Omega-3 polyunsaturated fatty acids inhibit the proliferation of the lung adenocarcinoma cell line A549 in vitro. Molecular Medicine Reports, 9(2), 401–406.
170. Yang, P., Cartwright, C., Chan, D., Ding, J., Felix, E., Pan, Y., et al. (2014). Anticancer activity of fish oils against human lung cancer is associated with changes in formation of PGE2 and PGE3 and alteration of Akt phosphorylation. Molecular Carcinogenesis, 53(7), 566–577.
171. Casas-Rodera, P., Gomez-Candela, C., Benitez, S., Mateo, R., Armero, M., Castillo, R., et al. (2008). Immunoenhanced enteral nutrition formulas in head and neck cancer surgery: a prospective, randomized clinical trial. Nutrición Hospitalaria, 23(2), 105–110.
172. Felekis, D., Eleftheriadou, A., Papadakos, G., Bosinakou, I., Ferekidou, E., Kandiloros, D., et al. (2010). Effect of perioperative immuno-enhanced enteral nutrition on inflammatory response, nutritional status, and outcomes in head and neck cancer patients undergoing major surgery. Nutrition and Cancer, 62(8), 1105–1112.
173. de Luis, D. A., Izaola, O., Aller, R., Cuellar, L., Terroba, M. C., & Martin, T. (2008). A randomized clinical trial with two omega 3 fatty acid enhanced oral supplements in head and neck cancer ambulatory patients. European Review for Medical and Pharmacological Sciences, 12(3), 177–181.
174. de Luis, D. A., Izaola, O., Cuellar, L., Terroba, M. C., de la Fuente, B., & Cabezas, G. (2013). A randomized clinical trial with two doses of a omega 3 fatty acids oral and arginine enhanced formula in clinical and biochemical parameters of head and neck cancer ambulatory patients. European Review for Medical and Pharmacological Sciences, 17(8), 1090–1094.
175. Vasson, M. P., Talvas, J., Perche, O., Dillies, A. F., Bachmann, P., Pezet, D., et al. (2014). Immunonutrition improves functional capacities in head and neck and esophageal cancer patients undergoing radiochemotherapy: a randomized clinical trial. Clinical Nutrition, 33(2), 204–210.
176. Machon, C., Thezenas, S., Dupuy, A. M., Assenat, E., Michel, F., Mas, E., et al. (2012). Immunonutrition before and during radiochemotherapy: improvement of inflammatory parameters in head and neck cancer patients. Support Care Cancer, 20(12), 3129–3135.
177. Aiko, S., Yoshizumi, Y., Tsuwano, S., Shimanouchi, M., Sugiura, Y., & Maehara, T. (2005). The effects of immediate enteral feeding with a formula containing high levels of omega-3 fatty acids in patients after surgery for esophageal cancer. JPEN Journal of Parenteral and Enteral Nutrition, 29(3), 141–147.
178. Aiko, S., Yoshizumi, Y., Ishizuka, T., Horio, T., Sakano, T., Kumano, I., et al. (2008). Enteral immuno-enhanced diets with arginine are safe and beneficial for patients early after esophageal cancer surgery. Diseases of the Esophagus, 21(7), 619–627.
179. Long, H., Yang, H., Lin, Y., Situ, D., & Liu, W. (2013). Fish oil-supplemented parenteral nutrition in patients following esophageal cancer surgery: effect on inflammation and immune function. Nutrition and Cancer, 65(1), 71–75.
180. Mudge, L., Isenring, E., & Jamieson, G. G. (2011). Immunonutrition in patients undergoing esophageal cancer resection. Diseases of the Esophagus, 24(3), 160–165.
181. von Haehling, S., & Anker, S. D. (2010). Cachexia as a major underestimated and unmet medical need: facts and numbers. Journal of Cachexia, Sarcopenia and Muscle, 1(1), 1–5.
182. Morley, J. E., Thomas, D. R., & Wilson, M.-M. G. (2006). Cachexia: pathophysiology and clinical relevance. The American Journal of Clinical Nutrition, 83(4), 735–743.
183. Fearon, K. C. (2011). Cancer cachexia and fat–muscle physiology. New England Journal of Medicine, 365(6), 565–567.
184. Chamberlain, J. S. (2004). Cachexia in cancer-zeroing in on myosin. New England Journal of Medicine, 351, 2124–2125.
185. Hopkinson, J. B., Wright, D. N., McDonald, J. W., & Corner, J. L. (2006). The prevalence of concern about weight loss and change in eating habits in people with advanced cancer. Journal of Pain and Symptom Management, 32(4), 322–331.
186. Inui, A. (2002). Cancer anorexia‐cachexia syndrome: current issues in research and management. CA: a Cancer Journal for Clinicians, 52(2), 72–91.
187. MacDonald, N., Easson, A. M., Mazurak, V. C., Dunn, G. P., & Baracos, V. E. (2003). Understanding and managing cancer cachexia. Journal of the American College of Surgeons, 197(1), 143–161.
188. Gullett, N. P., Mazurak, V., Hebbar, G., & Ziegler, T. R. (2011). Nutritional interventions for cancer-induced cachexia. Current Problems in Cancer, 35(2), 58.
189. Andreyev, H., Norman, A., Oates, J., & Cunningham, D. (1998). Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? European Journal of Cancer, 34(4), 503–509.
190. O'Gorman, P., McMillan, D. C., & McArdle, C. S. (1998). Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients. Nutrition and Cancer 32(2):76–80.
191. Tisdale, M. J. (2002). Cachexia in cancer patients. Nature Reviews Cancer, 2(11), 862–871.
192. Windsor, J. A., & Hill, G. L. (1988). Risk factors for postoperative pneumonia. The importance of protein depletion. Annals of Surgery, 208(2), 209.
193. Smith, K., & Tisdale, M. (1993). Increased protein degradation and decreased protein synthesis in skeletal muscle during cancer cachexia. British Journal of Cancer, 67, 680–680.
194. Khal, J., Wyke, S., Russell, S. T., Hine, A. V., & Tisdale, M. J. (2005). Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia. British Journal of Cancer, 93(7), 774–780.
195. Acharyya, S., Butchbach, M. E., Sahenk, Z., Wang, H., Saji, M., Carathers, M., et al. (2005). Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell, 8(5), 421–432.
196. Tisdale, M. J. (2009). Mechanisms of cancer cachexia. Physiological Reviews, 89(2), 381–410.
197. Das, S. K., Eder, S., Schauer, S., Diwoky, C., Temmel, H., Guertl, B., et al. (2011). Adipose triglyceride lipase contributes to cancer-associated cachexia. Science, 333(6039), 233–238.
198. Lira, F. S., Rosa, J. C., Zanchi, N. E., Yamashita, A. S., Lopes, R. D., Lopes, A. C., et al. (2009). Regulation of inflammation in the adipose tissue in cancer cachexia: effect of exercise. Cell Biochemistry and Function, 27(2), 71–75.
199. Sharma, R., & Anker, S. D. (2002). Cytokines, apoptosis and cachexia: the potential for TNF antagonism. International Journal of Cardiology, 85(1), 161–171.
200. Bing, C., Bao, Y., Jenkins, J., Sanders, P., Manieri, M., Cinti, S., et al. (2004). Zinc-α2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proceedings of the National Academy of Sciences of the United States of America, 101(8), 2500–2505.
201. Tisdale, M. J. (2003). Pathogenesis of cancer cachexia. Journal of Supportive Oncology, 1(3), 159–168.
202. Zhou, W., Jiang, Z.-W., Tian, J., Jiang, J., Li, N., & Li, J.-S. (2003). Role of NF-kB and cytokine in experimental cancer cachexia. World Journal of Gastroenterology, 9(7), 1567–1570.
203. Argilés, J. M., Busquets, S., Toledo, M., & López-Soriano, F. J. (2009). The role of cytokines in cancer cachexia. Current Opinion in Supportive and Palliative Care, 3(4), 263–268.
204. Langstein, H. N., Doherty, G. M., Fraker, D. L., Buresh, C. M., & Norton, J. A. (1991). The roles of γ-interferon and tumor necrosis factor α in an experimental rat model of cancer cachexia. Cancer Research, 51(9), 2302–2306.
205. Kumar, N. B., Kazi, A., Smith, T., Crocker, T., Yu, D., Reich, R. R., et al. (2010). Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Current Treatment Options in Oncology, 11(3-4), 107–117.
206. Granda-Cameron, C., DeMille, D., Lynch, M. P., Huntzinger, C., Alcorn, T., Levicoff, J., et al. (2010). An interdisciplinary approach to manage cancer cachexia. Clinical Journal of Oncology Nursing, 14(1), 72–80.
207. Berquin, I. M., Edwards, I. J., & Chen, Y. Q. (2008). Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Letters, 269(2), 363–377.
208. Tisdale, M. J., & Dhesi, J. K. (1990). Inhibition of weight loss by ω-3 fatty acids in an experimental cachexia model. Cancer Research, 50(16), 5022–5026.
209. Russell, S., & Tisdale, M. (2005). Effect of eicosapentaenoic acid (EPA) on expression of a lipid mobilizing factor in adipose tissue in cancer cachexia. Prostaglandins, Leukotrienes and Essential Fatty Acids, 72(6), 409–414.
210. Whitehouse, A. S., Smith, H. J., Drake, J. L., & Tisdale, M. J. (2001). Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Research, 61(9), 3604–3609.
211. Hussey, H., & Tisdale, M. (1999). Effect of a cachectic factor on carbohydrate metabolism and attenuation by eicosapentaenoic acid. British Journal of Cancer, 80(8), 1231.
212. Price, S. A., & Tisdale, M. J. (1998). Mechanism of inhibition of a tumor lipid-mobilizing factor by eicosapentaenoic acid. Cancer Research, 58(21), 4827–4831.
213. Ohira, T., Nishio, K., Ohe, Y., Arioka, H., Nishio, M., Funayama, Y., et al. (1996). Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation. Journal of Cancer Research and Clinical Oncology, 122(12), 711–715.
214. Tisdale, M. J. (1996). Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia. Nutrition, 12(1), S31–S33.
215. Beck, S. A., Smith, K. L., & Tisdale, M. J. (1991). Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Research, 51(22), 6089–6093.
216. Tisdale, M. J., & Beck, S. A. (1991). Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. Biochemical Pharmacology, 41(1), 103–107.
217. Jho, D. H., Babcock, T. A., Tevar, R., Helton, W. S., & Espat, N. J. (2002). Eicosapentaenoic acid supplementation reduces tumor volume and attenuates cachexia in a rat model of progressive non-metastasizing malignancy. Journal of Parenteral and Enteral Nutrition, 26(5), 291–297.
218. Dauchy, R. T., Blask, D. E., Sauer, L. A., Davidson, L. K., Krause, J. A., Smith, L. C., et al. (2003). Physiologic melatonin concentration, omega-3 fatty acids, and conjugated linoleic acid inhibit fatty acid transport in rodent hind limb skeletal muscle in vivo. Comparative Medicine, 53(2), 186–190.
219. Ogilvie, G. K., Fettman, M. J., Mallinckrodt, C. H., Walton, J. A., Hansen, R. A., Davenport, D. J., et al. (2000). Effect of fish oil, arginine, and doxorubicin chemotherapy on remission and survival time for dogs with lymphoma. Cancer, 88(8), 1916–1928.
220. Tisdale, M. (1993). Mechanism of lipid mobilization associated with cancer cachexia: interaction between the polyunsaturated fatty acid, eicosapentaenoic acid, and inhibitory guanine nucleotide-regulatory protein. Prostaglandins, Leukotrienes and Essential Fatty Acids, 48(1), 105–109.
221. Damsbo-Svendsen, S., Rønsholdt, M. D., & Lauritzen, L. (2013). Fish oil-supplementation increases appetite in healthy adults a randomized controlled cross-over trial. Appetite, 66, 62–66.
222. Cerchietti, L. C., Navigante, A. H., & Castro, M. A. (2007). Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutrition and Cancer, 59(1), 14–20.
223. Murphy, R., Yeung, E., Mazurak, V., & Mourtzakis, M. (2011). Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia. British Journal of Cancer, 105(10), 1469–1473.
224. Weed, H. G., Ferguson, M. L., Gaff, R. L., Hustead, D. S., Nelson, J. L., & Voss, A. C. (2011). Lean body mass gain in patients with head and neck squamous cell cancer treated perioperatively with a protein‐and energy‐dense nutritional supplement containing eicosapentaenoic acid. Head & Neck, 33(7), 1027–1033.
225. Harle, L., Brown, T., Laheru, D., & Dobs, A. S. (2005). Omega-3 fatty acids for the treatment of cancer cachexia: issues in designing clinical trials of dietary supplements. Journal of Alternative and Complementary Medicine: Research on Paradigm, Practice, and Policy, 11(6), 1039–1046.
226. Barber, M., Ross, J., Voss, A., Tisdale, M., & Fearon, K. (1999). The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. British Journal of Cancer, 81(1), 80.
227. Moses, A., Slater, C., Preston, T., Barber, M., & Fearon, K. (2004). Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. British Journal of Cancer, 90(5), 996–1002.
228. Barber, M. D., Fearon, K. C., Tisdale, M. J., McMillan, D. C., & Ross, J. A. (2001). Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. Nutrition and Cancer, 40(2), 118–124.
229. Hamamura, K., Nakaya, M., Nakagawa, M., Miyazaki, M., & Miki, C. (2011). A case of stage IV rectal cancer with whom EPA oral nutritional supplements could resolve cachectic condition and promote patient compliance with cancer chemotherapy. Gan to Kagaku Ryoho Cancer and Chemotherapy, 38(5), 845–848.
230. Kanat, O., Cubukcu, E., Avci, N., Budak, F., Ercan, I., Canhoroz, M., et al. (2012). Comparison of three different treatment modalities in the management of cancer cachexia. Tumori, 99(2), 229–233.
231. Yeh, K.-Y., Wang, H.-M., Chang, J. W.-C., Huang, J.-S., Lai, C.-H., Lan, Y.-J., et al. (2013). Omega-3 fatty acid-, micronutrient-, and probiotic-enriched nutrition helps body weight stabilization in head and neck cancer cachexia. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 116(1), 41–48.
232. Wigmore, S. J., Fearon, K. C., Maingay, J. P., & Ross, J. A. (1997). Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clinical Science, 92(Pt 2), 215–221.
233. Wigmore, S. J., Ross, J. A., Stuart Falconer, J., Plester, C. E., Tisdale, M. J., Carter, D. C., et al. (1996). The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition, 12(1), S27–S30.
234. Colomer, R., Moreno-Nogueira, J. M., García-Luna, P. P., García-Peris, P., García-de-Lorenzo, A., Zarazaga, A., et al. (2007). N-3 fatty acids, cancer and cachexia: a systematic review of the literature. British Journal of Nutrition, 97(05), 823–831.
235. Dewey, A., Baughan, C., Dean, T., Higgins, B., & Johnson, I. (2007). Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev, 1.
236. Fearon, K. C., Barber, M. D., Moses, A. G., Ahmedzai, S. H., Taylor, G. S., Tisdale, M. J., et al. (2006). Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. Journal of Clinical Oncology, 24(21), 3401–3407.
237. Ries, A., Trottenberg, P., Elsner, F., Stiel, S., Haugen, D., Kaasa, S., et al. (2012). A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project. Palliative Medicine, 26(4), 294–304.
238. Mazzotta, P., & Jeney, C. M. (2009). Anorexia-cachexia syndrome: a systematic review of the role of dietary polyunsaturated fatty acids in the management of symptoms, survival, and quality of life. Journal of Pain and Symptom Management, 37(6), 1069–1077.
239. Stehr, S. N., & Heller, A. R. (2006). Omega-3 fatty acid effects on biochemical indices following cancer surgery. Clinica Chimica Acta, 373(1), 1–8.
240. Smith, G. I., Atherton, P., Reeds, D. N., Mohammed, B. S., Rankin, D., Rennie, M. J., et al. (2011). Omega-3 polyunsaturated fatty acids augment the muscle protein anabolic response to hyperinsulinaemia-hyperaminoacidaemia in healthy young and middle-aged men and women. Clinical Science, 121(6), 267–278.
241. Mantovani, G., Macciò, A., Madeddu, C., Gramignano, G., Lusso, M. R., Serpe, R., et al. (2006). A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiology, Biomarkers & Prevention, 15(5), 1030–1034.
242. Mantovani, G., Macciò, A., Madeddu, C., Serpe, R., Massa, E., Dessì, M., et al. (2010). Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. The Oncologist, 15(2), 200–211.
243. Brown, T. T., Zelnik, D. L., & Dobs, A. S. (2003). Fish oil supplementation in the treatment of cachexia in pancreatic cancer patients. International Journal of Gastrointestinal Cancer, 34(2-3), 143–150.
244. Smith, H. J., Greenberg, N., & Tisdale, M. J. (2004). Effect of eicosapentaenoic acid, protein and amino acids on protein synthesis and degradation in skeletal muscle of cachectic mice. British Journal of Cancer, 91(2), 408–412.
245. Mcmillan, D. (2004). Modulation of the liver export protein synthetic response to feeding by an n-3 fatty-acid-enriched nutritional supplement is associated with anabolism in cachectic cancer patients. Clinical Science, 106, 359–364.
246. Burns, C. P., Halabi, S., Clamon, G. H., Hars, V., Wagner, B. A., Hohl, R. J., et al. (1999). Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. Clinical Cancer Research, 5(12), 3942–3947.
247. Ghosh, S., DeCoffe, D., Brown, K., Rajendiran, E., Estaki, M., Dai, C., et al. (2013). Fish oil attenuates omega-6 polyunsaturated fatty acid-induced dysbiosis and infectious colitis but impairs LPS dephosphorylation activity causing sepsis. PLoS ONE, 8(2), e55468.
248. Calder, P. C. (2004). n-3 Fatty acids, inflammation, and immunity—relevance to postsurgical and critically III patients. Lipids, 39(12), 1147–1161.
249. Xia, S., Li, X., Cheng, L., Han, M., Zhang, M., Liu, X., et al. (2014). Chronic intake of high fish oil diet induces myeloid-derived suppressor cells to promote tumor growth. Cancer Immunology, Immunotherapy, 1–11.
250. Brasky, T. M., Till, C., White, E., Neuhouser, M. L., Song, X., Goodman, P., et al. (2011). Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. American Journal of Epidemiology, 173(12), 1429–1439.
251. Miller, M. R., Pereira, R. I., Langefeld, C. D., Lorenzo, C., Rotter, J. I., Chen, Y.-D. I., et al. (2012). Levels of free fatty acids (FFA) are associated with insulin resistance but do not explain the relationship between adiposity and insulin resistance in Hispanic Americans: the IRAS Family Study. The Journal of Clinical Endocrinology and Metabolism, 97(9), 3285–3291.
252. Sarbolouki, S., Javanbakht, M. H., Derakhshanian, H., Hosseinzadeh, P., Zareei, M., Hashemi, S. B., et al. (2013). Eicosapentaenoic acid improves insulin sensitivity and blood sugar in overweight type 2 diabetes mellitus patients: a double-blind randomised clinical trial. Singapore Medical Journal, 54(7), 387–390.
253. Lichtenstein, A. H., Kennedy, E., Barrier, P., Danford, D., Ernst, N. D., Grundy, S. M., et al. (1998). Dietary fat consumption and health. Nutrition Reviews, 56(5), 3–19.
254. Hlais, S., El-Bistami, D., El Rahi, B., Mattar, M. A., & Obeid, O. A. (2013). Combined fish oil and high oleic sunflower oil supplements neutralize their individual effects on the lipid profile of healthy men. Lipids, 48(9), 853–861.
255. Ozyazgan, S., Karaoglu, K., Kurt, A., Altinok, A., Konukoglu, D., Osar, S. Z., et al. (2013). Effects of omega-3 polyunsaturated fatty acid supplementation on serum fetuin-a levels in type 2 diabetic patients. Minerva Medica, 104(3), 287–293.
256. Giacco, R., Cuomo, V., Vessby, B., Uusitupa, M., Hermansen, K., Meyer, B. J., et al. (2007). Fish oil, insulin sensitivity, insulin secretion and glucose tolerance in healthy people: Is there any effect of fish oil supplementation in relation to the type of background diet and habitual dietary intake of n-6 and n-3 fatty acids? Nutrition Metabolism and Cardiovascular Diseases, 17(8), 572–580.
257. Mostad, I. L., Bjerve, K. S., Bjorgaas, M. R., Lydersen, S., & Grill, V. (2006). Effects of n-3 fatty acids in subjects with type 2 diabetes: reduction of insulin sensitivity and time-dependent alteration from carbohydrate to fat oxidation. The American Journal of Clinical Nutrition, 84(3), 540–550.
258. Galgani, J. E., Uauy, R. D., Aguirre, C. A., & Díaz, E. O. (2008). Effect of the dietary fat quality on insulin sensitivity. British Journal of Nutrition, 100(03), 471–479.
259. De Caterina, R., Madonna, R., Bertolotto, A., & Schmidt, E. B. (2007). n-3 Fatty acids in the treatment of diabetic patients biological rationale and clinical data. Diabetes Care, 30(4), 1012–1026.
260. Hartweg, J., Perera, R., Montori, V., Dinneen, S., Neil, H., & Farmer, A. (2008). Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst Rev, 1.
261. Hartweg, J., Farmer, A. J., Holman, R. R., & Neil, A. (2009). Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes. Current Opinion in Lipidology, 20(1), 30–38.
262. Hendrich, S. (2010). (n-3) fatty acids: clinical trials in people with type 2 diabetes. Advances in Nutrition: an International Review Journal, 1(1), 3–7.
263. Tremoli, E., Maderna, P., Marangoni, F., Colli, S., Eligini, S., Catalano, I., et al. (1995). Prolonged inhibition of platelet aggregation after n-3 fatty acid ethyl ester ingestion by healthy volunteers. The American Journal of Clinical Nutrition, 61(3), 607–613.
264. Nordøy, A., Bønaa, K. H., Sandset, P. M., Hansen, J.-B., & Nilsen, H. (2000). Effect of ω-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 20(1), 259–265.
265. Barcelli, U., Glas-Greenwalt, P., & Pollak, V. E. (1985). Enhancing effect of dietary supplementation with ω-3 fatty acids on plasma fibrinolysis in normal subjects. Thrombosis Research, 39(3), 307–312.
266. Vanschoonbeek, K., Feijge, M. A., Paquay, M., Rosing, J., Saris, W., Kluft, C., et al. (2004). Variable hypocoagulant effect of fish oil intake in humans modulation of fibrinogen level and thrombin generation. Arteriosclerosis, Thrombosis, and Vascular Biology, 24(9), 1734–1740.
267. Vanschoonbeek, K., Wouters, K., van der Meijden, P. E., van Gorp, P. J., Feijge, M. A., Herfs, M., et al. (2008). Anticoagulant effect of dietary fish oil in hyperlipidemia a study of hepatic gene expression in APOE2 knock-in mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(11), 2023–2029.
268. Goodnight, S. J., Harris, W. S., & Connor, W. E. (1981). The effects of dietary omega 3 fatty acids on platelet composition and function in man: a prospective, controlled study. Blood, 58(5), 880–885.
269. Knapp, H. R. (1997). Dietary fatty acids in human thrombosis and hemostasis. The American Journal of Clinical Nutrition, 65(5), 1687S–1698S.
270. von Schacky, C., & Weber, P. C. (1985). Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. Journal of Clinical Investigation, 76(6), 2446–2450.
271. Calò, L., Bianconi, L., Colivicchi, F., Lamberti, F., Loricchio, M. L., de Ruvo, E., et al. (2005). N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. Journal of the American College of Cardiology, 45(10), 1723–1728.
272. Meredith, D. S., Kepler, C. K., Hirsch, B., Nguyen, J., Farmer, J. C., Girardi, F. P., et al. (2012). The effect of omega-3 fatty-acid supplements on perioperative bleeding following posterior spinal arthrodesis. European Spine Journal, 21(12), 2659–2663.
273. Heller, A., Fischer, S., Rössel, T., Geiger, S., Siegert, G., Ragaller, M., et al. (2002). Impact of n-3 fatty acid supplemented parenteral nutrition on haemostasis patterns after major abdominal surgery. British Journal of Nutrition, 87(S1), S95–S101.
274. Cohen, M. G., Rossi, J. S., Garbarino, J., Bowling, R., Motsinger-Reif, A. A., Schuler, C., et al. (2011). Insights into the inhibition of platelet activation by omega-3 polyunsaturated fatty acids: beyond aspirin and clopidogrel. Thrombosis Research, 128(4), 335–340.
275. Wachira, J. K., Larson, M. K., & Harris, W. S. (2014). n-3 Fatty acids affect haemostasis but do not increase the risk of bleeding: clinical observations and mechanistic insights. British Journal of Nutrition, 111(09), 1652–1662.